Tarlatamab With Anti-PD-L1 Demonstrates OS Benefit as First-Line Maintenance Therapy After Chemo-IO in ES-SCLC - ILCN.org (ILCN/WCLC) Lead investigator Dr. Kelly Paulson said the combination demonstrated unprecedented overall survival with a manageable safety profile in this patient population.

#WCLC25 recap: Tarlatamab + anti-PD-L1 demonstrated OS benefit as 1L maintenance therapy after chemo-IO in ES-SCLC.

Learn more in ILCN: bit.ly/49czUCq

LCC in Georgian: WCLC 2025 Highlights | IASLC The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer resear ...

In this #LungCancerConsidered episode, Dr. Elene Mariamidze speaks with Dr. Salome Begijanashvili, Dr. Beka Shubitidze & Dr. Mariam Tchiabrishvili in Georgian about the most impactful #WCLC25 data and clinical updates.

Listen now: bit.ly/WCLC25Georgian #Georgia #Georgian

Lessons from ECOG-ACRIN E4512: Could Limited Gains Lead to Positive Direction in Refining Adjuvant Therapy? - ILCN.org (ILCN/WCLC) Discussant Dr. Jessica L. Lin said the results won't change clinical practice after Dr. David Gerber reported no differences in OS or DFS.

#WCLC25 recap: Dr. Jessica J. Lin explains how the ECOG-ACRIN E4512 results won't change clinical practice. Read why in a new ILCN article: http://bit.ly/3W1SPdd #lungcancer #research

LCC in Japanese: WCLC 2025 Highlights | IASLC The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer resear ...

In this Japanese-language episode, Dr. Misako Nagasaka moderates a discussion with @hhorinouchi.bsky.social on highlights from #WCLC25, including FLAURA2 and HARMONi.

Listen to their insights on emerging lung cancer treatment: http://bit.ly/3Jl3Cwi

#LungCancer #Oncology #IASLC

Novel Meta-Analysis Shows VATS Improves Overall Survival in Early-Stage Lung Cancer - ILCN.org (ILCN/WCLC) Dr. Jacie Jiaqi Law shared results from a first-ever meta-analysis demonstrating that VATS reduces mortality risk without compromising disease-free survival.

At #WCLC25, Dr. Jacie Law shared results from a first-ever meta-analysis demonstrating that VATS reduces mortality risk without compromising disease-free survival.
Learn more: bit.ly/3L1hPie

From the floor of #WCLC25, our Director of Research & Clinical Affairs, Dr. Ken Culver, spoke with Lung Cancers Today about the latest advances in lung cancer research.

👉 Watch the video & read the full article: www.lungcancerstoday.com/post/new-dat...

Perioperative Nivolumab Proves Safe, Effective for Patients with Resectable Early-Stage NSCLC - ILCN.org (ILCN/WCLC) Dr. Jonathan Spicer shared patient-reported outcomes data from CheckMate 77T showing the regimen is both safe and tolerable for patients.

♟️ CheckMate for perioperative nivolumab? Dr. Jonathan Spicer presented the latest data from the CheckMate 77T trial at #WCLC25.

🔗 Read more in ILCN: bit.ly/46m612v

Dr. Devika Das, a member of LCRF’s Education + Engagement committee, shares her thoughts on #WCLC25 in this video.

Today at 3:30pm ET, our Together Separately livestream will feature more discussion about this important conference. Sign up to join us: LCRF.org/together

youtu.be/5LX1XcETxHU?...

Ivonescimab-Chemotherapy Combo Shows Promise as Post-TKI Option in EGFR-Mutant NSCLC - ILCN.org (ILCN/WCLC) Dr. Jonathan W. Goldman reported that ivonescimab plus chemotherapy yielded a consistent PFS benefit across subgroups.

Could ivonescimab plus chemo be a promising post-TKI option in EGFR-mutant NSCLC? 🤔

🔗 Read the highlights from #WCLC25 in ILCN
#LCSM

Dr Eric K. Singhi’s Top 5 Studies From WCLC 2025: A Thoracic Oncologist’s Perspective Dr Eric K. Singhi shares his top 5 presentations from WCLC 2025 and explains why he finds them compelling.

Dr Eric K. Singhi (@lungoncdoc.bsky.social) of @mdanderson.bsky.social shares his top 5 presentations from #WCLC25 and explains why he finds them compelling. Read his thoughts here: shorturl.at/ThK4z #lcsm

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy - ILCN.org (ILCN/WCLC) Dr. David Planchard said the findings support a combination approach as a first-line treatment with an extended overall survival advantage for patients with EGFRm advanced NSCLC.

🚨 Breaking from #WCLC25: Final OS results from the FLAURA2 trial.
🔗 Read the highlights from the first Presidential Symposium in ILCN: bit.ly/48l4oU2

#LCSM

#WCLC25 It takes a village!

Thanks to all our dedicated editors, reviewers, our publisher and my editorial office teams! Thanks for the support from our authors and @iaslc.bsky.social!

@jtoonline.bsky.social @elsevierhms.bsky.social #JTO #JTOCRR

#WCLC25 Meet the Editors - Engaging Q&A session between meeting attendees and Editors-in-Chief, Dr Alex Adjei #JTO and Dr Emily Stone #JTOCRR.

@iaslc.bsky.social @jtoonline.bsky.social @elsevierhms.bsky.social #scholarlypublishing

A fresh episode of LCC is out!

Dr. Alona Zer moderates a conversation with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel on the major takeaways from #WCLC25, including clinical advances, research highlights, and global perspectives on lung cancer.

Start Listening: bit.ly/48l1M8E

Narjust Florez: A Meaningful Week of Science at the WCLC25 - OncoDaily Narjust Florez: A Meaningful Week of Science at the WCLC25 / cancer, Lung cancer, Narjust Florez, OncoDaily, Oncology, WCLC25

A Meaningful Week of Science at the WCLC25 - Narjust Florez

@narjustflorezmd.bsky.social

oncodaily.com/voices/narju...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC25

First-line treatment with sotorasib, bevacizumab, and chemotherapy demonstrated activity in patients with KRAS G12C-mutant, advanced #NSCLC, according to research presented at #WCLC25. shorturl.at/FpFA2 #lcsm

Jarushka Naidoo: Best Slides of WCLC25 by Daniel Tan - OncoDaily Jarushka Naidoo: Best Slides of WCLC25 by Daniel Tan / cancer, Daniel Tan, FLAURA2, Jarushka Naidoo, NSCLC, OncoDaily, Oncology, WCLC25

Best Slides of WCLC25 by Daniel Tan - Jarushka Naidoo

@drjnaidoo.bsky.social

oncodaily.com/voices/wclc2...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #WCLC25

Osimertinib Plus Chemo May Be Effective After Progression on Osimertinib Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

Adding osimertinib to platinum-based chemo may boost outcomes for patients with EGFR+ advanced NSCLC after progression on 1L osimertinib, new data show at #WCLC25.
#LungCancer #EGFR #CancerResearch #TCSC

www.cancertherapyadvisor.com/reports/osim...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced #NSCLC who had disease progression on first-line osimertinib. Presented at #WCLC25. #lcsm shorturl.at/ADG1h

Reflecting on a successful #WCLC25! Our team shared our work with University Health Network Toronto on advancing ctDNA analysis in #NSCLC with Foresight CLARITY™ and connected with colleagues, collaborators and others dedicated to improving outcomes in #lungcancer. More details: bit.ly/4gmQh2t

Tarlatamab Plus Anti–PD-L1 as Frontline Maintenance Shows Unprecedented OS in ES-SCLC | OncLive Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab Plus Anti–PD-L1 as Frontline Maintenance Shows Unprecedented OS in ES-SCLC @iaslc.bsky.social #WCLC25 #lcsm #oncology #medtwitter www.onclive.com/view/tarlata...

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC | OncLive Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC @iaslc.bsky.social #WCLC25 #lcsm #medtwitter #oncology www.onclive.com/view/tarlata...

New research at #WCLC25 looked at a tool to support shared decision-making in ALK+ #LungCancer.

Choosing a first treatment isn’t only about the data - it’s about what matters most to each person: quality of life, side effects, work, family, or travel.

Decisions should be shared. #LCSM

IMM2510 Induces Early Efficacy in Advanced, Immunotherapy-Exposed Squamous NSCLC The PD-L1– and VEGF-directed bispecific antibody IMM2510 proved active in patients with squamous NSCLC after prior chemotherapy and immunotherapy.

IMM2510 Induces Early Efficacy in Advanced, Immunotherapy-Exposed Squamous NSCLC @iaslc.bsky.social #WCLC25 #lcsm #oncology
www.onclive.com/view/imm2510...

Results from the HARMONi trial suggest the efficacy of ivonescimab + chemo differs between patients in China and those in North America or Europe. Presented at #WCLC25 by Dr Jonathan Goldman of UCLA Health. Discussed by @ramalingammd.bsky.social of @winshipcancer.emory.edu. #lcsm shorturl.at/nijIh

Adjuvant Chemoimmunotherapy for Resected Stage IB–IIIA NSCLC Interim results from the phase III NADIM ADJUVANT trial, presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC), suggest that adjuv...

NADIM ADJUVANT
#IASLC #WCLC25

Mary Pasquinelli, DNP, APRN, FNP-BC, presented findings on Sybil—a deep learning AI model predicting future #lungcancer risk in a predominantly Black population—at #WCLC25 in Barcelona.

Senior author: Frank Weinberg, MD, PhD (UI Health)

bit.ly/3IeeSde

Ateganosine Sequenced With Cemiplimab Displays Activity in Pretreated NSCLC Ateganosine sequenced with cemiplimab was active in advanced NSCLC after disease progression on 2 or more standard therapies.

Ateganosine Sequenced With Cemiplimab Displays Activity in Pretreated NSCLC @iaslc.bsky.social #WCLC25 #lcsm #oncology
www.onclive.com/view/ategano...

Congratulations to friends at Nuvalent on the exciting and pivotal #ARROS1 data released @iaslc.bsky.social #WCLC25. Proud to continue to collaborate on outcomes for our patient community globally. 💙
#LCSM

Highlights From IASLC WCLC 2025: 35 Posts Not to Miss - OncoDaily Highlights From IASLC WCLC 2025: 35 Posts Not to Miss / Balazs Halmos, Bingnan Zhang, Blerina Resuli, cancer, Eric K. Singhi, Fabrizio T, IASLC, Iolanda

Highlights From IASLC WCLC 2025: 35 Posts Not to Miss

@iaslc.bsky.social @stephenvliu.bsky.social @drjnaidoo.bsky.social @patrickforde.bsky.social @yvonnediaz.bsky.social

oncodaily.com/insight/high...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IASLC #WCLC #WCLC25